Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM6 | O15303 | 1/20 | 0.54 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2771075 | 1.00 | GRM6 (0.54) | GRM6GBA1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL2771498 | 1.00 | GRM6 (0.54) | GRM6GBA1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL2587055 | 0.90 | CYP1A2 (0.60) | GRM6SMN1; SMN2CYP1A2CYP2C19NPSR1 | |
| SCHEMBL1819248 | 0.90 | CYP1A2 (0.60) | GRM6SMN1; SMN2CYP1A2CYP2C19NPSR1 | |
| SCHEMBL1972076 | 0.90 | CYP1A2 (0.60) | GRM6SMN1; SMN2CYP1A2CYP2C19NPSR1 | |
| SCHEMBL8319384 | 0.89 | SIGMAR1 (0.55) | SMN1; SMN2MEN1TSHRKMT2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL20790624 | 0.88 | CYP1A2 (0.59) | GRM6SMN1; SMN2CYP1A2CYP2C19NPSR1 | |
| SCHEMBL3713831 | 0.88 | SMN1; SMN2 (0.63) | SMN1; SMN2CYP1A2CYP2C19NPSR1CD274 | |
| Hydrochloric Acid SCHEMBL992443 | 0.88 | CYP1A2 (0.59) | GRM6SMN1; SMN2CYP1A2CYP2C19NPSR1 | |
| SCHEMBL3713829 | 0.88 | SMN1; SMN2 (0.63) | SMN1; SMN2CYP1A2CYP2C19NPSR1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1057894-B1 | Esterase genes and uses of the same | SUMITOMO CHEMICAL CO (JP) | 2010-04-28 | — | — | EP | disclosed |
| EP-0974670-B1 | Process for producing optically active N-substituted azetidine-2-carboxylic acid compound | SUMITOMO CHEMICAL CO (JP) | 2006-09-13 | — | — | EP | disclosed |
| EP-1308519-B1 | Process for improving optical purity of azetidine-2-carboxylic acid | SUMITOMO CHEMICAL CO (JP) | 2006-04-19 | — | — | EP | disclosed |
| US-6828129-B2 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-12-07 | — | — | US | disclosed |
| US-6812008-B2 | NUCLEOTIDE SEQUENCES CODING POLYPEPTIDE FOR USE IN THE GENERATION OF S-N-BENZYLAZETIDINE-2-CARBOXYLIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-02 | — | — | US | disclosed |
| EP-1308519-A1 | Process for improving optical purity of azetidine-2-carboxylic acid | Sumitomo Chemical Company, Limited (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-0855446-B1 | Process for producing optically active azetidine-2-carboxylic acid derivative | SUMITOMO CHEMICAL CO (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6537790-B1 | Isolated protein of given sequence which can produce N-substituted cyclic imino acids by hydrolization | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-25 | — | — | US | disclosed |
| US-20020173013-A1 | Esterace genes and uses of the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-11-21 | — | — | US | disclosed |
| US-20020164727-A1 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-11-07 | — | — | US | disclosed |
| US-6410279-B1 | GENERATING PREFERENTIAL COMPOUND IN SOLUTION; OBTAIN N-SUBSTITUTED AZETIDINE-2-CARBOXYLIC ACID ESTER, INCUBATE WITH PREFERENTIAL ENZYME, RECOVER COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| US-6162621-A | Process for producing optically active azetidine-2-carboxylic acid derivative | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2000-12-19 | — | — | US | disclosed |
| EP-1057894-A2 | Esterase genes and uses of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-06 | — | — | EP | disclosed |
| US-6143554-A | Process for producing optically active n-substituted azetidine-2 carboxylic acid compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-11-07 | — | — | US | disclosed |
| EP-0974670-A2 | Process for producing optically active N-substituted azetidine-2-carboxylic acid compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-01-26 | — | — | EP | disclosed |
| EP-0855446-A2 | Process for producing optically active azetidine-2-carboxylic acid derivative | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020164727-A1 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | IMPDH2, INHA, IMPDH1 | GRM6 3961/4885GBA1 2740/4885SMN1; SMN2 3197/4885 |
| US-20020173013-A1 | Esterace genes and uses of the same | ACOT7, COASY, IMPA1 | GRM6 4074/4885GBA1 1222/4885SMN1; SMN2 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.